Pfizer forecasts 2024 revenue below Wall Street expectations. On Wednesday, Pfizer (PFE.N) announced that it would be lowering its cost-cutting objective by $500 million and forecasting revenue for 2024 that would be lower than what Wall Street had anticipated.
The American pharmaceutical company estimates that its annual sales will be between $58.5 billion and $61.5 billion, significantly higher than the experts’ average prediction of $63.17 billion. For instance, it considers the contribution that Seagen’s product sales made.
During the past two years, Pfizer’s income has increased because of the sales of Paxlovid and the vaccine it manufactures with its German partner BioNTech (22UAy.DE). This enabled the company to generate over $100 billion in 2022.
However, due to a decrease in yearly vaccination rates and demand for the treatments, the corporation was compelled to initiate a program in October to reduce the number of workers and expenditures and secure savings of up to $3.5 billion.
The corporation, which has over 83,000 workers worldwide, eliminated 500 positions at its Sandwich, Kent location in the United Kingdom in November. In premarket trading, the company’s shares saw a one percent decline.
The variance between Wall Street’s estimate and Pfizer’s forecast for 2024 warrants scrutiny. While financial models and market sentiment may impact Wall Street projections, Pfizer’s forecast is likely to consider complex internal data, strategic initiatives, and market insights.
Pfizer’s conservative forecast might stem from a pragmatic approach, considering potential market volatility, regulatory uncertainties, or strategic adjustments within the company.
